This list is an analysis based on recent market events. It's not an investment recommendation.
About
Health Technology
Pharmaceuticals: Generic
Manufacturing
Pharmaceutical Preparation Manufacturing
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
Show more...
CEO
Richard Chin
Employees
63
Country
US
Listings
0 Comments
Share your thoughts
FAQ
What is Kindred Biosciences stock price today?▼
The current price of KIN is $9.25 USD — it has increased by +0.11% in the past 24 hours. Watch Kindred Biosciences stock price performance more closely on the chart.
What is Kindred Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kindred Biosciences stocks are traded under the ticker KIN.
What is Kindred Biosciences market cap?▼
Today Kindred Biosciences has the market capitalization of 420.53M
How many employees does Kindred Biosciences have?▼
As of April 03, 2026, the company has 63 employees.
In which sector is Kindred Biosciences located?▼
Kindred Biosciences operates in the Manufacturing sector.
When did Kindred Biosciences complete a stock split?▼
Kindred Biosciences has not had any recent stock splits.
Where is Kindred Biosciences headquartered?▼
Kindred Biosciences is headquartered in Burlingame, US.